Blogs
What Happened to the Pharma Reps?
Dr. Jack Cush weighs in on changes in pharmaceutical "detailing" with suggestions for the future.
ICYMI: A Shortage of Trust
I wanted to complain about patients who complain, but guilt and common sense took over. I intended to declare the problem to primarily belong to the doctor, rather than the patient. To me, the solution to the patient’s consternation should begin and end with the source: me (you). My introspection, reasonings, and commandments were fine, but I kept running into the enigma of “Trust” – which can either be a speed-bump or chasm in our physician-patient relationships.A Card-Carrying Optimist
I may be a snarky, opinionated curmudgeon, but I'm an optimist when and where it counts. And I think you should join me.ICYMI: The Biosimilar "Buy In"
The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients. Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023.


